Abstract: The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas. wherein A is —(CH2)a—CH?CH—(CH 2)5-a—H where a is from 0 to 5, —(CH2)b—CH?CH—(CH 2)6-b—H where b is from 0 to 6, —(CH2)c—CH?CH—(CH 2)7-c—H where c is from 0 to 7, —(CH2)d—CH?CH—(CH 2)8-d—H where d is from 0 to 8, or —CH2)e—CH?CH—(CH 2)9-d—H where d is from 0 to 9; B is hydrogen or C1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

Abstract: The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to compositions, methods of use and methods of manufacturing of a transdermal delivery systems, patches, vehicles and devices used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.

Abstract: The present disclosure relates to compositions, methods of use and methods of manufacturing of a transdermal delivery systems, patches, vehicles and devices used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.

Abstract: The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas. wherein A is —(CH2)a—CH?CH—(CH 2)5-a—H where a is from 0 to 5, —(CH2)b—CH?CH—(CH 2)6-b—H where b is from 0 to 6, —(CH2)c—CH?CH—(CH 2)7-c—H where c is from 0 to 7, —(CH2)d—CH?CH—(CH 2)8-d—H where d is from 0 to 8, or —CH2)e—CH?CH—(CH 2)9-d—H where d is from 0 to 9; B is hydrogen or C1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

Abstract: A fabric is saturated with a salt solution, such that when an electric current is applied to the fabric, the fabric exhibits a bactericidal ability. In another aspect, a salt solution includes a conductor, a humectant, a solvent, and a binder, where the conductor has an NaCl % w/w of between 3 and 11, the humectant has a glycerol % w/w of between 3 and 15, the solvent has a water % w/w of between 77 and 89 and the fixative includes a binder % w/w of between 0.01 and 2.0.

Abstract: The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas. wherein A is —(CH2)a-CH?CH—(CH 2)5-a-H where a is from 0 to 5, —(CH2)b-CH?CH—(CH 2)6-b-H where b is from 0 to 6, —(CH2)c-CH?CH—(CH 2)7-c-H where c is from 0 to 7, —(CH2)d-CH?CH—(CH 2)8-d-H where d is from 0 to 8, or —CH2)e-CH?CH—(CH 2)9-d-H where d is from 0 to 9; B is hydrogen or C1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

Abstract: The present disclosure relates to exosome bone graft systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

Abstract: The aspects of the disclosed embodiments relate to exosome systems and compositions and preservative systems and compositions including systems and compositions including diatomic oxygen as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to exosome systems and compositions and preservative systems and compositions including systems and compositions including diatomic oxygen as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.

Abstract: The present disclosure relates to imparting a cooling effect on textiles or fabrics by treating them and incorporating sugar alcohol and carbonate compositions.

Abstract: The present disclosure relates to compositions, methods of use and methods of manufacturing of transdermal delivery systems, patches, vehicles and devices including an iontophoretic transdermal delivery system, patch, vehicle or device used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.

Abstract: The present disclosure relates to compositions, methods of use and methods of manufacturing of a transdermal delivery systems, patches, vehicles and devices used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.

Abstract: The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas. wherein A is —(CH2)a-CH?CH—(CH 2)5-a-H where a is from 0 to 5, —(CH2)b-CH?CH—(CH 2)6-b-H where b is from 0 to 6, —(CH2)c-CH?CH—(CH 2)7-c-H where c is from 0 to 7, —(CH2)d-CH?CH—(CH 2)5-d-H where d is from 0 to 8, or —CH2)e-CH?CH—(CH 2)9-d-H where d is from 0 to 9; B is hydrogen or C1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

Abstract: The present disclosure relates to anhydrous hydrogels useful as mucoadhesive (oral compositions) or as topical agents and may be used to deliver an active agent such as active pharmaceutical agents (API's), coagulants, fragrances, flavors, and other actives and excipients.

Abstract: The present disclosure relates to anhydrous hydrogels useful as mucoadhesive (oral compositions) or as topical agents and may be used to deliver an active agent such as active pharmaceutical agents (API's), coagulants, fragrances, flavors, and other actives and excipients.

Abstract: The present disclosure relates to anhydrous hydrogels useful as mucoadhesive (oral compositions) or as topical agents and may be used to deliver an active agent such as active pharmaceutical agents (API's), coagulants, fragrances, flavors, and other actives and excipients.

Abstract: The present disclosure relates to anhydrous hydrogels useful as mucoadhesive (oral compositions) or as topical agents and may be used to deliver an active agent such as active pharmaceutical agents (API's), coagulants, fragrances, flavors, and other actives and excipients.

Abstract: The present disclosure relates to anhydrous hydrogels useful as mucoadhesive (oral compositions) or as topical agents and may be used to deliver an active agent such as active pharmaceutical agents (API's), coagulants, fragrances, flavors, and other actives and excipients.